Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity

Journal of Virology

Volumn 86, Issue 4, 2012, Pages 2045-2055

  Euler, Zelda ^a   van den Kerkhof, Tom L G M ^a   van Gils, Marit J ^a   Burger, Judith A ^a   Edo Matas, Diana ^a   Phung, Pham ^b   Wrin, Terri ^b   Schuitemaker, Hanneke ^a,c  

^a SANQUIN RESEARCH   (Netherlands)

^b MONOGRAM BIOSCIENCES   (United States)

^c CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 160; NEUTRALIZING ANTIBODY;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONGITUDINAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEROCONVERSION; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

COHORT STUDIES; CROSS REACTIONS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; NEUTRALIZATION TESTS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84857084577     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06091-11     Document Type: Article

References (45)

1. Beaumont T, et al. 2001. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J. Virol. 75:2246-2252.
2. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
3. Bonsignori M, et al. 2011. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85:9998-10009.
4. Boom R, et al. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
5. Bunnik EM, et al. 2010. Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 16:995-997.
6. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82:7932-7941.
7. Burton DR, et al. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. U. S. A. 108:11181-11186.
8. Curlin ME, et al. 2010. HIV-1 envelope subregion length variation during disease progression. PLoS Pathog. 6:e1001228.
9. + cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J. Infect. Dis. 158: 615-622.
10. Doria-Rose NA, et al. 2010. Breadth of human immunodeficiency virusspecific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84:1631-1636.
11. Edo-Matas D, et al. 2010. Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. Virology 405:492-504.
12. Euler Z, et al. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201:1045-1053.
13. + T cell decline and high viral load during acute infection. J. Virol. 85:4828-4840.
14. Hall TA. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids Symp. Ser. 41:95-98.
15. Hessell AJ, et al. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15: 951-954.
16. Hessell AJ, et al. 2009. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5:e1000433.
17. Reference deleted.
18. Mahalanabis M, et al. 2009. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J. Virol. 83:662-672.
19. Mascola JR, et al. 2000. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-210.
20. McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554.
21. Mikell I, et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251.
22. Moore PL, et al. 2009. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5:e1000598.
23. Mouquet H, et al. 2010. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467:591-595.
24. Pancera M, et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
25. Pereyra F, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-571.
26. Petropoulos CJ, et al. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
27. Piantadosi A, et al. 2009. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 83:10269-10274.
28. Quakkelaar ED, et al. 2007. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. J. Virol. 81:8533-8542.
29. Rademeyer C, et al. 2007. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 368:172-181.
30. Richman DD, Wrin T, Little SJ, Petropoulos CJ. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100:4144-4149.
31. Rong R, et al. 2009. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5:e1000594.
32. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
33. Scheid JF, et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
34. Schuitemaker H, et al. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J. Virol. 66:1354-1360.
35. Simek MD, et al. 2009. HIV-1 elite neutralizers: individuals with broad and potent neutralizing activity identified using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-7348.
36. Tersmette M, et al. 1989. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 171:149-155.
37. van Gils MJ, et al. 2011. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J. Virol. 85:6986-6995.
38. van Gils MJ, et al. 2010. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors. J. Virol. 84:3576-3585.
39. van Gils MJ, Euler Z, Schweighardt B, Wrin T, Schuitemaker H. 2009. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 23:2405-2414.
40. van't Wout AB, et al. 1994. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral and vertical transmission. J. Clin. Invest. 94:2060-2067.
41. van't Wout AB, Schuitemaker H, Kootstra NA. 2008. Isolation and propagation of HIV-1 on peripheral blood mononuclear cells. Nat. Protoc. 3:363-370.
42. Wei X, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312.
43. Yuan T, et al. 2011. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development. Vaccine 29:6903-6910.
44. Zhang M, et al. 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14:1229-1246.
45. Zhou T, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.